Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
20 hedge funds and large institutions have $5.56M invested in Medicenna Therapeutics Corp. Common Shares in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.3% less ownership
Funds ownership: 8.23% → 7.94% (-0.3%)
13% less funds holding
Funds holding: 23 → 20 (-3)
25% less capital invested
Capital invested by funds: $7.42M → $5.56M (-$1.85M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCWS
McKinley Carter Wealth Services
Wheeling,
West Virginia
|
+$104K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$93.6K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$90.7K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$90.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$32.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IIM
Intact Investment Management
Montreal,
Quebec, Canada
|
-$444K |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$110K |
| 3 |
Renaissance Technologies
New York
|
-$92.1K |
| 4 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$17K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8K |
MDNA Hedge Fund Activity: Q1 2022 in Review
20 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q1 2022, worth a combined $5.56M — down 25% from $7.42M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MDNA and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was McKinley Carter Wealth Services, adding an estimated $104K. The largest seller was Intact Investment Management, cutting an estimated $444K.
- 20 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q1 2022, down from 23 in Q4 2021.
- Funds reported $5.56M of Medicenna Therapeutics Corp. Common Shares stock for Q1 2022, down 25% quarter-over-quarter.
- 2 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q1 2022 and 5 closed out, a net change of -3 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q1 2022 was McKinley Carter Wealth Services, an estimated $104K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q1 2022 was Intact Investment Management, an estimated $444K sold.
Based on aggregated 13F filings for Q1 2022.